Sad to hear that news about Mexico.

NP has been uncharacteristically silent these days. Makes complete sense given all that is (confidentially) happening behind the scenes. Also makes sense given the fact that uplisting will require a completely different approach for communicating with investors.

He might as well shift protocols now -- and ease into the way big, successful companies disclose information. And we should all probably prepare for a very different communications experience compared to what we have grown accustomed to.

Anyway, my point was, it would seem the Mexico trial has been killed. I could see it being killed by the FDA, I could see the FDA telling CytoDyn to kill it, and I could see Mexico deciding that it just made more sense to wait and approve on the basis of the FDA.

The sad part is that regardless of Mexico approving, they must realize that they are not going to get the drug for several months (or maybe next year) if the FDA approves. And this sad fact unfortunately applies to every other country in the world, unless Samsung and AGC are somehow able to ramp up production significantly.